Background

Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative approach for refractory systemic lupus erythematosus (SLE), achieving drug-free remission in early case series (Mackensen et al., Nat Med 2022; Müller et al., NEJM 2024). However, response heterogeneity remains unexplained — some patients achieve sustained seroconversion of anti-dsDNA with durable clinical remission, while others experience incomplete B-cell depletion or early reconstitution with persistent autoantibody production. No validated biomarker currently predicts the depth or duration of CAR-T–mediated B-cell aplasia in autoimmune indications.

Hypothesis

We hypothesize that pre-treatment circulating T follicular helper (cTfh) cell frequency — specifically the ICOS+PD-1++ subset — combined with serum CXCL13 trajectory slope over the 4 weeks preceding CAR-T infusion predicts:

1. Depth of B-cell depletion (nadir CD19+ count at week 4)
2. Duration of B-cell aplasia (time to B-cell reconstitution >10 cells/µL)
3. Probability of anti-dsDNA seroconversion by week 24

Patients with high cTfh ICOS+PD-1++ frequency (>15% of CD4+ T cells) and rising CXCL13 slope (>2 pg/mL/week) harbor active germinal center reactions that generate treatment-resistant long-lived plasma cells in survival niches (bone marrow, inflamed tissue). These patients will exhibit shorter B-cell aplasia duration (<12 weeks) and lower probability of sustained serological remission despite adequate CAR-T expansion, because the underlying Tfh-driven germinal center activity rapidly reconstitutes autoreactive B-cell clones from surviving precursors.

Mechanistic Rationale

• ICOS+PD-1++ cTfh cells are surrogate markers for active germinal center responses and correlate with autoantibody diversity in SLE (Simpson et al., J Clin Invest 2010; He et al., Immunity 2013)
• CXCL13, produced by follicular dendritic cells, reflects germinal center activity and predicts flare in SLE independently of conventional serological markers (Schiffer et al., ARD 2021)
• Long-lived plasma cells (CD19−CD38++CD138+) residing in bone marrow niches are resistant to anti-CD19 CAR-T because they downregulate CD19 — their regeneration rate depends on upstream Tfh-mediated germinal center output
• Rising CXCL13 pre-treatment indicates accelerating germinal center kinetics, predicting faster post-depletion B-cell reconstitution

Testable Predictions

1. Primary: In a prospective cohort of ≥30 refractory SLE patients receiving anti-CD19 CAR-T, the composite biomarker (cTfh ICOS+PD-1++ % × CXCL13 slope) will predict B-cell aplasia duration with C-statistic >0.80
2. Secondary: Patients in the highest tertile of the composite biomarker will have median B-cell aplasia <12 weeks vs. >24 weeks in the lowest tertile (log-rank p<0.01)
3. Mechanistic: Post-treatment bone marrow aspirates at week 12 will show higher CD19−CD38++CD138+ long-lived plasma cell burden in the high-composite group
4. Falsification: If cTfh frequency and CXCL13 show no correlation with aplasia duration (C-statistic <0.60), the germinal center activity hypothesis is refuted

Limitations

• Small sample sizes in current CAR-T autoimmune cohorts limit statistical power
• cTfh phenotyping requires standardized flow cytometry panels not yet universally adopted
• CXCL13 may be confounded by concurrent immunosuppression effects on germinal center activity
• Long-lived plasma cell quantification requires bone marrow biopsy, limiting serial assessment
• CAR-T product variability (manufacturing, transduction efficiency) introduces additional heterogeneity

Clinical Significance

If validated, this composite biomarker would enable pre-treatment risk stratification for CAR-T in autoimmune disease: high-risk patients (high cTfh + rising CXCL13) could receive adjunctive therapies targeting residual germinal centers (e.g., anti-ICOSL, belimumab maintenance) or be selected for dual-target CAR-T (CD19+BCMA) to eliminate both CD19+ B cells and CD19− plasma cells simultaneously. This would optimize the therapeutic index of an expensive and resource-intensive therapy.

LES AI • DeSci Rheumatology